Sage Readies Zurzuvae For December Launch With Slow Ramp As Payer Talks Progress
No Update On Plans For MDD Resubmission
Sage and Biogen set a $15,900 list price for Zurzuvae, the 14-day postpartum depression drug approved in the US in August, and expect broad access but formulary discussions will continue into 2024.
You may also be interested in...
CEO Chris Viehbacher outlined progress Biogen made in the third quarter, including full approval for the Eisai-partnered Alzheimer’s drug Leqembi, but recent wins will take time to make up for long-term revenue declines.
I.V. Zulresso is the first US FDA-approved drug for postpartum depression (PPD) and Sage's first commercial product – with a list price of $34,000. It will help the company build a presence in PPD as it completes late-stage development for oral candidate SAGE-217.
Less than two years after its $101m series A round, Seismic’s machine-learning powered IMPACT platform for biologics drug discovery yielded two clinical trial-ready assets worthy of a $121m series B.